 Connection
Natalie Serkova to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Natalie Serkova has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.637 |
|
|
|
-
Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol. 2009 Sep; 158(2):588-600.
Score: 0.313
-
Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015 Mar 15; 21(6):1360-72.
Score: 0.114
-
Serkova NJ, Freund AS, Brown JL, Kominsky DJ. Use of the 1-mm micro-probe for metabolic analysis on small volume biological samples. J Cell Mol Med. 2009 Aug; 13(8B):1933-1941.
Score: 0.078
-
Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 2009 May 15; 15(10):3442-50.
Score: 0.077
-
Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res. 2004 Oct 01; 10(19):6661-8.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|